Anticoagulant therapy in COVID‐19: A narrative review
Z Mohseni Afshar, A Tavakoli Pirzaman… - Clinical and …, 2023 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …
[HTML][HTML] Anticoagulant treatment in COVID-19: a narrative review
V Carfora, G Spiniello, R Ricciolino, M Di Mauro… - Journal of thrombosis …, 2021 - Springer
Abstract The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
[HTML][HTML] Hypercoagulability in COVID-19 and post-COVID patients-characteristics and current treatment guidelines
Thromboprophylaxis has become an essential part of coronavirus-induced disease 2019
(COVID-19) therapeutic modality. A debate is ongoing as to which specific anticoagulant …
(COVID-19) therapeutic modality. A debate is ongoing as to which specific anticoagulant …
[HTML][HTML] Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked
to a higher risk of mortality compared to influenza, which is mainly due to severe secondary …
to a higher risk of mortality compared to influenza, which is mainly due to severe secondary …
Anticoagulation for COVID-19 patients: a bird's-eye view
F Kreidieh, S Temraz - Clinical and Applied Thrombosis …, 2021 - journals.sagepub.com
Coronavirus disease 2019 (COVID-19) is a systemic disease that can be life-threatening
involving immune and inflammatory responses, and that can result in potentially lethal …
involving immune and inflammatory responses, and that can result in potentially lethal …
Anticoagulation in COVID-19: current concepts and controversies
A Chandra, U Chakraborty, S Ghosh… - Postgraduate medical …, 2022 - academic.oup.com
Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …
Anticoagulation in COVID-19: A review of current literature and guidelines
B Narasimhan, M Lorente-Ros… - Hospital …, 2021 - Taylor & Francis
Severe acute respiratory syndrome coronavirus 2 infections are associated with greater risk
of both arterial and venous thromboembolic events. Pathophysiology and Clinical …
of both arterial and venous thromboembolic events. Pathophysiology and Clinical …
[HTML][HTML] Management of thrombotic complications in COVID-19: an update
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …
[HTML][HTML] The role of anticoagulation in COVID-19-induced hypercoagulability
JS Rico-Mesa, D Rosas, A Ahmadian-Tehrani… - Current cardiology …, 2020 - Springer
Abstract Purpose of Review We aim to provide a comprehensive analysis of
hypercoagulability in individuals affected by COVID-19. Our goal is to describe the …
hypercoagulability in individuals affected by COVID-19. Our goal is to describe the …
[HTML][HTML] Anticoagulant therapy for patients with coronavirus disease 2019: urgent need for enhanced awareness
M Komiyama, K Hasegawa - European Cardiology Review, 2020 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 …
syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 …